The safety and efficacy of azimycin 1% eye drops on patients with posterior blepharitis multi-center study

The safety and efficacy of AZM eye drops on patients with MGD -multi-center study - The efficacy of AZM eye drops on MGD -multi-center study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037713

Enrollment

100

Registered

2019-09-09

Start date

2019-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posterior blepharitis

Interventions

azmycin eyed drops plus warming eyelid/warming eyelids warming eyelids

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) age is more than 18 years old 2) both gender is available 3) consent form is available 4) those who were defined as meibomian gland dysfunction 5) those who were defined as hyper-secretory MGD 6) Lid margin abnormalities 7) ocular symptoms 8) plugging and hypo-secretory MGD

Exclusion criteria

Exclusion criteria: StevensJohnson syndrome acute ocular inflammation ocular surface andor eye lid abnormalities allergic conjunctivitis CL wear Ocular surgery history within 3 months systemic diseases which might interfere with tear function inappropriate characters 9) ocular diseases except cataract or refractive error

Design outcomes

Primary

Measure	Time frame
ocular symptoms, lid margin abnormalities,quality and quantity of meibum, tear film breakup time, meiboscore	—

Countries

Japan

Contacts

Public ContactReiko Arita

Itoh Clinic Ophthalmology

ritoh@za2.so-net.ne.jp0486865588

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026